Cadence Pharmaceuticals, Inc. (CADX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-24.29M
Depreciation	213K
(Gain) loss on disposal of assets	0
Impairment of long-lived assets
Stock-based compensation	7.07M
Non-cash interest expense
Amortization of intangible assets	1.34M
Amortization of discount on note payable	497K
Amortization of premiums on available-for-sale securities, net of accretion of discounts	-1K
Accounts receivable	-3.15M
Inventory	-2.15M
Prepaid expenses and other current assets	-830K
Accounts payable	1.93M
Deferred revenue	-2.23M
Accrued liabilities and other liabilities	6.05M
Net cash used in operating activities	-23.19M
Purchases of marketable securities	0
Maturities of marketable securities
Investment in unconsolidated subsidiary
Restricted cash	0
Purchases of property and equipment	-505K
Proceeds from the sale of property and equipment	80K
Net cash used in investing activities	15.65M
Proceeds from issuance of common stock, net	4.29M
Borrowings under debt agreements, net of fees	0
Payments under debt agreements	0
Net cash provided by financing activities	4.29M
Net decrease in cash and cash equivalents	-3.25M
Cash and cash equivalents at beginning of period	58.33M
Cash and cash equivalents at end of period	55.08M
Issuance of warrants in connection with loan and security agreement	0
Shares in unconsolidated entity acquired in option purchase agreement
Property and equipment purchases in accounts payable and accrued expenses	232K
Cash paid for interest and fees	3.25M

Entities mentioned with CADX

View All Entities